DK2395990T3 - Materiale og fremgangsmåder til behandling af udviklingsforstyrrelser indbefattende co-morbid og idiopatisk autisme - Google Patents
Materiale og fremgangsmåder til behandling af udviklingsforstyrrelser indbefattende co-morbid og idiopatisk autisme Download PDFInfo
- Publication number
- DK2395990T3 DK2395990T3 DK10705949.5T DK10705949T DK2395990T3 DK 2395990 T3 DK2395990 T3 DK 2395990T3 DK 10705949 T DK10705949 T DK 10705949T DK 2395990 T3 DK2395990 T3 DK 2395990T3
- Authority
- DK
- Denmark
- Prior art keywords
- dose
- treatment
- composition
- autism
- acamprosate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (15)
1. Sammensætning, der indbefatter mindst ét element udvalgt fra gruppen bestående af acetylaminopropansulfonat og et acetylaminopropansulfonatsalt, til anvendelse i behandlingen af et individ med fragilt X-syndrom.
2. Sammensætning, der indbefatter mindst ét element udvalgt fra gruppen bestående af acetylaminopropansulfonat og et acetylaminopropansulfonatsalt, til anvendelse i behandlingen af et individ med en autismespektrumforstyrrelse.
3. Sammensætning til anvendelse ifølge krav 2, hvor autismespektrumforstyrrelsen indbefatter Aspergers syndrom.
4. Sammensætning til anvendelse ifølge krav 2, hvor autismespektrumforstyrrelsen indbefatter en idiopatisk autisme.
5. Sammensætning til anvendelse ifølge krav 2, hvor autismespektrumforstyrrelsen indbefatter en uspecificeret gennemgribende udviklingsforstyrrelse.
6. Sammensætning til anvendelse ifølge krav 1 eller krav 2, hvor elementet udvalgt fra gruppen bestående af acetylaminopropansulfonat og et acetylaminopropansulfonatsalt reducerer den neuronale glutamaterge signalering.
7. Sammensætning til anvendelse ifølge krav 1 eller krav 2, hvor acetylaminopropansulfonatsaltet indbefatter calciumacetylaminopropansulfonat repræsenteret ved formlen I:
8. Sammensætning til anvendelse ifølge krav 7, hvor calciumacetylaminopropansulfonatet er til administration til individet ved en dosis på mindst ét element udvalgt fra gruppen bestående af: en 333 mg dosis; en 666 mg dosis; en 999 mg dosis; en 1332 mg dosis; en 1665 mg dosis; en 1998 mg dosis; en 2331 mg dosis; en 2664 mg dosis og en 2997 mg dosis.
9. Sammensætning til anvendelse ifølge krav 8, hvilken sammensætning er formuleret til daglig administration af dosen til individet i en enkelt dosis.
10. Sammensætning til anvendelse ifølge krav 8, hvilken sammensætning er formuleret til daglig administration af dosen til individet i flere doser, såsom tre doser dagligt.
11. Sammensætning til anvendelse ifølge krav 1 eller krav 2, hvor individet er et menneske.
12. Sammensætning til anvendelse ifølge krav 10, det indbefatter formlen I:
til anvendelse i behandlingen af et menneske med fragilt X-syndrom, hvor anvendelsen sker ved administration af sammensætningen til det menneskelige individ i en dosis på 333 mg ved en frekvens på mindst ét element udvalgt fra gruppen bestående af to gange dagligt og tre gange dagligt.
13. Sammensætning til anvendelse ifølge krav 10, der indbefatter formlen I:
til anvendelse i behandlingen af et menneske med en autismespektrumforstyrrelse, hvor anvendelsen sker ved administration af sammensætningen til det menneskelige individ i en dosis på 333 mg ved en frekvens på mindst ét element udvalgt fra gruppen bestående af to gange dagligt og tre gange dagligt.
14. Sammensætning til anvendelse ifølge krav 2 eller krav 13, hvor individet endvidere har et fragilt X-syndrom.
15. Sammensætning til anvendelse ifølge krav 1 eller krav 12, hvor individet endvidere har en autismespektrumforstyrrelse.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15185809P | 2009-02-12 | 2009-02-12 | |
| PCT/US2010/024008 WO2010093859A1 (en) | 2009-02-12 | 2010-02-12 | Material and methods for treating developmental disorders including comorbid and idiopathic autism |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2395990T3 true DK2395990T3 (da) | 2015-02-23 |
Family
ID=42103866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10705949.5T DK2395990T3 (da) | 2009-02-12 | 2010-02-12 | Materiale og fremgangsmåder til behandling af udviklingsforstyrrelser indbefattende co-morbid og idiopatisk autisme |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9463172B2 (da) |
| EP (1) | EP2395990B1 (da) |
| JP (1) | JP5688035B2 (da) |
| AU (1) | AU2010213683B2 (da) |
| CA (1) | CA2781830C (da) |
| DK (1) | DK2395990T3 (da) |
| ES (1) | ES2530047T3 (da) |
| HR (1) | HRP20150120T1 (da) |
| PL (1) | PL2395990T3 (da) |
| PT (1) | PT2395990E (da) |
| SI (1) | SI2395990T1 (da) |
| WO (1) | WO2010093859A1 (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110294879A1 (en) * | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
| US20130296430A1 (en) * | 2012-05-03 | 2013-11-07 | Antonio Hardan | Compositions and methods for treating autism and autism spectrum disorder |
| CA2879113C (en) * | 2012-07-22 | 2021-11-16 | Indiana University Research And Technology Corporation | Modulation sapp, sapp alpha and bdnf levels in individuals diagnosed with fxs and asd |
| EP3878445A3 (en) * | 2013-06-05 | 2021-10-27 | Synchroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| AU2014337504B2 (en) | 2013-10-14 | 2020-01-30 | Indiana University Research And Technology Corporation | Use of acamprosate to modulate ERK 1-2 activation in animal models for FXS and ASD and individuals diagnosed with FXS and ASD |
| US10357469B2 (en) | 2015-02-18 | 2019-07-23 | Aston University | Diagnostic assay and treatment for preeclampsia |
| EP3291800A4 (en) | 2015-05-04 | 2018-09-26 | Confluence Pharmaceuticals, LLC | Sprinkle formulations of acamprosate |
| US20180221315A1 (en) * | 2015-08-04 | 2018-08-09 | Confluence Pharmaceuticals, Llc | Combination therapy using acamprosate and d-cycloserine |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602150A (en) | 1992-10-02 | 1997-02-11 | Research Foundation For Mental Hygiene, Inc. | Treatment of central nervous system disorders associated with psychotic behavior and dementia with a combination of neuroleptic drugs and taurine, or derivatives thereof, to prevent the development of tardive dyskinesia |
| US6294583B1 (en) | 1998-01-13 | 2001-09-25 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders |
| US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| US6890931B2 (en) | 2001-04-02 | 2005-05-10 | Brown University | Methods of treating disorders with group I mGluR antagonists |
| US6916821B2 (en) * | 2001-04-02 | 2005-07-12 | Brown University | Methods of treating disorders with Group I mGluR antagonists |
| DE10129265A1 (de) | 2001-06-18 | 2003-01-02 | Hf Arzneimittelforsch Gmbh | Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie |
| US20040102525A1 (en) | 2002-05-22 | 2004-05-27 | Kozachuk Walter E. | Compositions and methods of treating neurological disease and providing neuroprotection |
| ES2819303T3 (es) | 2005-04-05 | 2021-04-15 | Univ Yale | Agentes moduladores del glutamato en el tratamiento de trastornos mentales |
| EP2578216A1 (en) | 2006-11-22 | 2013-04-10 | Seaside Therapeutics, Inc. | Methods of treating fragile x syndrome |
| WO2008086483A2 (en) | 2007-01-11 | 2008-07-17 | Braincells, Inc. | Modulation of neurogenesis with use of modafinil |
| US20100317715A1 (en) | 2007-12-21 | 2010-12-16 | Vollrath Benedikt | Methods for treating neuropsychiatric conditions |
-
2010
- 2010-02-12 WO PCT/US2010/024008 patent/WO2010093859A1/en active Application Filing
- 2010-02-12 PT PT107059495T patent/PT2395990E/pt unknown
- 2010-02-12 DK DK10705949.5T patent/DK2395990T3/da active
- 2010-02-12 EP EP10705949.5A patent/EP2395990B1/en active Active
- 2010-02-12 AU AU2010213683A patent/AU2010213683B2/en active Active
- 2010-02-12 ES ES10705949.5T patent/ES2530047T3/es active Active
- 2010-02-12 JP JP2011550249A patent/JP5688035B2/ja active Active
- 2010-02-12 SI SI201030861T patent/SI2395990T1/sl unknown
- 2010-02-12 US US13/201,014 patent/US9463172B2/en active Active
- 2010-02-12 PL PL10705949T patent/PL2395990T3/pl unknown
- 2010-02-12 CA CA2781830A patent/CA2781830C/en active Active
-
2015
- 2015-02-02 HR HRP20150120TT patent/HRP20150120T1/hr unknown
-
2016
- 2016-06-24 US US15/192,535 patent/US9956189B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20160303057A1 (en) | 2016-10-20 |
| HRP20150120T1 (hr) | 2015-05-08 |
| US20120016036A1 (en) | 2012-01-19 |
| EP2395990A1 (en) | 2011-12-21 |
| CA2781830C (en) | 2018-03-27 |
| EP2395990B1 (en) | 2015-01-07 |
| ES2530047T3 (es) | 2015-02-26 |
| AU2010213683B2 (en) | 2016-04-21 |
| WO2010093859A1 (en) | 2010-08-19 |
| US9463172B2 (en) | 2016-10-11 |
| US9956189B2 (en) | 2018-05-01 |
| JP2012517480A (ja) | 2012-08-02 |
| SI2395990T1 (sl) | 2015-04-30 |
| JP5688035B2 (ja) | 2015-03-25 |
| AU2010213683A1 (en) | 2011-09-01 |
| PL2395990T3 (pl) | 2015-04-30 |
| PT2395990E (pt) | 2015-02-09 |
| CA2781830A1 (en) | 2010-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9956189B2 (en) | Material and methods for treating developmental disorders including comorbid and idiopathic autism | |
| Erickson et al. | Brief report: acamprosate in fragile X syndrome | |
| CA2580619C (en) | Use of memantine (namenda) to treat autism, compulsivity, and impulsivity | |
| JP2010510314A (ja) | 精神遅滞、ダウン症候群、脆弱ｘ症候群および自閉症の治療方法 | |
| EP3442513B1 (en) | Use of cannabidiolic acid in the treatment of autism spectrum disorder and associated disorders | |
| MX2010007073A (es) | Uso de cannabinoides en combinacion con un farmaco antipsicotico. | |
| US20220202798A1 (en) | Use of pridopidine for the treatment of fragile x syndrome | |
| EA012036B1 (ru) | Мемантин для лечения расстройств поведения детского возраста | |
| WO2022150525A1 (en) | Mdma in the treatment of alcohol use disorder | |
| Snyder et al. | A review of the pharmacology and clinical profile of lumateperone for the treatment of schizophrenia | |
| Marcus et al. | Augmentation by escitalopram, but not citalopram or R‐citalopram, of the effects of low‐dose risperidone: Behavioral, biochemical, and electrophysiological evidence | |
| US20230181572A1 (en) | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder | |
| TW201605443A (zh) | 治療ｘ染色體脆折症及相關病症的方法 | |
| Rus et al. | Treatment of 95 post-Covid patients with SSRIs | |
| EP3952872B1 (en) | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder | |
| EP4337316A1 (en) | Therapeutic aminoindane compounds and compositions | |
| JP2022527865A (ja) | ストレスに対するセロトニン４受容体アゴニストの予防的有効性 | |
| US20230059709A1 (en) | Treatment of fragile x syndrome with cannabidiol | |
| WO2023172701A2 (en) | Therapeutic combinations, compositions, and methods for designing and producing entactogenic mindstates | |
| OA20885A (en) | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder. | |
| AU2011235981B2 (en) | Use of Memantine (Namenda) to Treat Autism, Compulsivity, and Impulsivity | |
| FR2976179A1 (fr) | Utilisation de la carpipramine dans le traitement de troubles psychiatriques et du developpement chez l'enfant et l'adolescent |